European Journal of Cancer最新文献

{"title":"Corrigendum to “Dose optimization in cancer drug development: Review and outcome of a multi-stakeholder workshop”[Eur. J. Cancer 226 (2025), 115593]","authors":"Axel Glasmacher , Elena Garralda , Chad Gwaltney , Katrin Rupalla , Chunze Li , Harald Weber","doi":"10.1016/j.ejca.2025.116044","DOIUrl":"10.1016/j.ejca.2025.116044","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"230 ","pages":"Article 116044"},"PeriodicalIF":7.1,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145269440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends and efficacy of definitive radiotherapy regimens for locally advanced head and neck cancer in elderly patients: A population-based analysis by the German cancer registry group","authors":"Inge Tinhofer ,&nbsp;Elena Hofmann ,&nbsp;Anna Trelinska-Finger ,&nbsp;Tannaz Saraei ,&nbsp;Ulrich Keilholz ,&nbsp;Max Heiland ,&nbsp;Anne Letsch ,&nbsp;Maren Knödler ,&nbsp;Marcus Beck ,&nbsp;Konrad Klinghammer ,&nbsp;Steffen Dommerich ,&nbsp;Ian Wittenberg ,&nbsp;Fabian Reinwald ,&nbsp;Andrea Sackmann ,&nbsp;Monika Klinkhammer-Schalke ,&nbsp;Sylke Ruth Zeissig ,&nbsp;Kerstin Weitmann ,&nbsp;Bianca Franke ,&nbsp;Constanze Schneider ,&nbsp;Daniel Zips ,&nbsp;Christian Doll","doi":"10.1016/j.ejca.2025.116039","DOIUrl":"10.1016/j.ejca.2025.116039","url":null,"abstract":"<div><h3>Background</h3><div>With increasing life expectancy, the number of elderly patients diagnosed with locally advanced head and neck squamous cell carcinoma (HNSCC) is rising. The effectiveness of definitive radiotherapy (RT) regimens in this population remains unclear. This study investigates RT regimen trends and their impact on overall survival (OS) and locoregional recurrence (LRR) in elderly HNSCC patients using a large German cancer registry dataset.</div></div><div><h3>Methods</h3><div>A retrospective analysis of 84,046 HNSCC cases from 2000 to 2022 was conducted. RT administration trends were assessed in patients aged ≤ 70 years and &gt; 70 years. OS and LRR were analyzed in patients receiving definitive RT alone or combined with chemotherapy (RCTx) or cetuximab (RT-Cet), using Kaplan-Meier estimates and multivariate Cox regression models.</div></div><div><h3>Results</h3><div>The proportion of elderly patients receiving definitive RT regimens increased significantly over time. Platinum-based RCTx remained the most frequently used regimen but was less common in patients &gt; 70 years than in younger patients (26 % vs. 57 %, P &lt; 0.001). Five-year OS following platinum-based RCTx was comparable between age groups (HR 1.01, P = 0.83). In contrast, RT-Cet was associated with significantly worse OS and higher LRR compared to platinum-based RCTx, with a stronger negative impact in patients &gt; 70 years (OS: HR 2.31, P &lt; 0.001; LRR: HR 2.11, P = 0.003) than ≤ 70 years (OS: HR 1.55 P &lt; 0.001; LRR: HR 1.43, P = 0.002). This age-related difference was not observed with RT alone.</div></div><div><h3>Conclusions</h3><div>Platinum-based RCTx remains the most effective treatment for elderly HNSCC patients. RT-Cet is associated with poorer outcome particularly in patients &gt; 70 years, underscoring the need for age-adapted, biology-informed treatment strategies.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"230 ","pages":"Article 116039"},"PeriodicalIF":7.1,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145243961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tarlatamab-induced immune-related adverse events: Real-world pharmacovigilance study using the FAERS database","authors":"Nikhil Vojjala,&nbsp;Muhammad Atif Khan,&nbsp;Nagaishwarya Moka,&nbsp;Joseph P. McGuirk,&nbsp;Prakash C. Neupane,&nbsp;Nausheen Ahmed","doi":"10.1016/j.ejca.2025.116038","DOIUrl":"10.1016/j.ejca.2025.116038","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"230 ","pages":"Article 116038"},"PeriodicalIF":7.1,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter Re: TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma: signal or noise?","authors":"Luca Bertolaccini,&nbsp;Filippo de Marinis,&nbsp;Lorenzo Spaggiari","doi":"10.1016/j.ejca.2025.116036","DOIUrl":"10.1016/j.ejca.2025.116036","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"230 ","pages":"Article 116036"},"PeriodicalIF":7.1,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to letter Re: Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient biliary tract cancer: An AGEO study","authors":"Marie Decraecker","doi":"10.1016/j.ejca.2025.116033","DOIUrl":"10.1016/j.ejca.2025.116033","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"230 ","pages":"Article 116033"},"PeriodicalIF":7.1,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient biliary tract cancer: An AGEO study","authors":"Shaoxiang Huang,&nbsp;Xueyu Wang,&nbsp;Peili Zhang","doi":"10.1016/j.ejca.2025.116032","DOIUrl":"10.1016/j.ejca.2025.116032","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"230 ","pages":"Article 116032"},"PeriodicalIF":7.1,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Specific targeting of the pseudogene RPSAP52 reduces ovarian tumor growth in patient-derived orthoxenograft models","authors":"Deepthi Ramesh-Kumar ,&nbsp;Anaís Sánchez-Castillo ,&nbsp;Marta Soler ,&nbsp;Juan Francisco Martin-Tejera ,&nbsp;Cristina Oliveira-Mateos ,&nbsp;Veronica Davalos ,&nbsp;Maria Martinez-Iniesta ,&nbsp;Mar Martinez-Lozano ,&nbsp;Monica Calaf ,&nbsp;August Vidal ,&nbsp;Alberto Villanueva ,&nbsp;Sonia Guil ,&nbsp;Lourdes Farre","doi":"10.1016/j.ejca.2025.116040","DOIUrl":"10.1016/j.ejca.2025.116040","url":null,"abstract":"<div><div>The <em>RPSAP52</em> pseudogene is transcribed in the opposite direction to the oncofetal gene <em>HMGA2</em> and is reexpressed in various human cancers. Here, we investigate the impact of <em>RPSAP52</em> in ovarian cancer (OC) and explore the potential therapeutic application of GapmeR antisense oligonucleotides against <em>RPSAP52</em> in preclinical models. <em>RPSAP52</em> and <em>HMGA2</em> expression were investigated in TCGA for OC and further explored in a panel of orthotopic PDXs and commercial cell lines by RT-qPCR. The Kaplan–Meier method was used to estimate survival associated with <em>RPSAP52</em> expression in a dataset within the OC TCGA cohort. The effect of specific silencing of <em>RPSAP52</em> on tumor growth <em>in vitro</em> and <em>in vivo</em> was evaluated by lentiviral-mediated depletion and antisense LNA GapmeRs against <em>RPSAP52</em>. The pseudogene <em>RPSAP52</em> was overexpressed in epithelial OC in both patient samples and OC preclinical models coinciding with the overexpression of <em>HMGA2</em>. Elevated expression levels of <em>RPSAP52</em> in the early stages of OC were associated with poorer clinical outcomes and could stratify patients in stages I and II. The specific depletion of <em>RPSAP52</em> led to a reduction in OC tumor growth <em>in vitro</em> and <em>in vivo</em>. Furthermore, the treatment with antisense LNA GapmeRs against <em>RPSAP52</em> showed significant antitumoral effect in OC cell lines and in a PDOX model (without evident toxicity). Our findings demonstrate that <em>RPSAP52</em> displays pro-growth features in OC, underscoring the significance of pseudogenes in cancer pathophysiology. This pseudogene has potential utility as therapeutic target in OC and as valuable prognostic biomarker for the early stages of this disease.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"230 ","pages":"Article 116040"},"PeriodicalIF":7.1,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145269439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Letter Re: TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma","authors":"Filippo Tommaso Gallina,&nbsp;Daniele Marinelli,&nbsp;Jonathan Spicer","doi":"10.1016/j.ejca.2025.116037","DOIUrl":"10.1016/j.ejca.2025.116037","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"230 ","pages":"Article 116037"},"PeriodicalIF":7.1,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145269441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab","authors":"Chiara Pirrone ,&nbsp;Umberto Malapelle ,&nbsp;Francesco Pepe ,&nbsp;Federica Lo Prinzi ,&nbsp;Federico Nichetti ,&nbsp;Anna Saborowski ,&nbsp;Lorenzo Antonuzzo ,&nbsp;Silvia Camera ,&nbsp;Tomoyuki Satake ,&nbsp;Frederik Peeters ,&nbsp;Caterina Vivaldi ,&nbsp;Tiziana Pressiani ,&nbsp;Jessica Lucchetti ,&nbsp;Jin Won Kim ,&nbsp;Oluseyi Abidoye ,&nbsp;Ilario Giovanni Rapposelli ,&nbsp;Stefano Tamberi ,&nbsp;Fabian Finkelmeier ,&nbsp;Guido Giordano ,&nbsp;Chiara Pircher ,&nbsp;Andrea Casadei-Gardini","doi":"10.1016/j.ejca.2025.116035","DOIUrl":"10.1016/j.ejca.2025.116035","url":null,"abstract":"<div><h3>Background</h3><div>Biliary tract cancers (BTC) are aggressive malignancies with limited therapeutic options. Recent advances have integrated immunotherapy into the standard of care, yet outcomes remain heterogeneous, emphasizing the need for molecular biomarkers to guide patient selection. This study aimed to assess the prognostic impact of pathway-level genomic alterations in patients with BTC treated with first-line cisplatin, gemcitabine, and durvalumab.</div></div><div><h3>Methods</h3><div>This retrospective, multicenter study included 735 patients with advanced BTC, of whom 197 underwent comprehensive genomic profiling using the FoundationOne® CDx assay. Pathways were classified based on the presence of key gene alterations, and their association with overall survival (OS) and progression-free survival (PFS) was assessed through univariate and multivariate analyses. Tumor mutational burden (TMB) was also evaluated as a potential biomarker.</div></div><div><h3>Results</h3><div><em>HRD/BRCAness</em> pathway alterations were associated with significantly improved OS (23.3 vs. 13.8 months, HR 0.51, 95 % CI 0.27–0.93, p = 0.0295) and PFS (13.2 vs. 8.1 months, HR 0.53, 95 % CI 0.32–0.89, p = 0.0153). TGF-β pathway alterations were linked to longer PFS (16.0 vs. 8.1 months, HR 0.53, 95 % CI 0.28–0.99, p = 0.0473) but did not independently predict OS. High TMB (&gt;10 mut/Mb) was associated with improved OS (NR vs. 11.0 months, HR 0.34, 95 % CI 0.14–0.85, p = 0.0206) and PFS (NR vs. 7.6 months, HR 0.40, 95 % CI 0.13–0.96, p = 0.043). However, no single pathway was significantly correlated with early treatment response.</div></div><div><h3>Conclusions</h3><div><em>HRD</em>/BRCA<em>ness</em> and TGF-β pathway alterations, along with high TMB, emerged as potential prognostic biomarkers in patients with BTC treated with chemo-immunotherapy. These findings, if prospectively confirmed and validated, support the integration of molecular profiling into routine clinical practice to improve patient stratification and treatment outcomes in this challenging tumor type.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"230 ","pages":"Article 116035"},"PeriodicalIF":7.1,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145269588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study” [Eur J Cancer. 2025;228:115748]","authors":"Akihiro Tsukaguchi ,&nbsp;Kinnosuke Matsumoto ,&nbsp;Akihiro Tamiya ,&nbsp;Motohiro Tamiya ,&nbsp;Masahide Mori ,&nbsp;Hidekazu Suzuki ,&nbsp;Takayuki Shiroyama ,&nbsp;Akito Miyazaki ,&nbsp;Kiyohide Komuta ,&nbsp;Yasuhiro Mihashi ,&nbsp;Keijiro Yamauchi ,&nbsp;Kensuke Kanaoka ,&nbsp;Tomoki Kuge ,&nbsp;Yuhei Kinehara ,&nbsp;Koji Azuma ,&nbsp;Toshie Niki ,&nbsp;Koki Moritomo ,&nbsp;Yoshito Takeda ,&nbsp;Atsushi Kumanogoh","doi":"10.1016/j.ejca.2025.116010","DOIUrl":"10.1016/j.ejca.2025.116010","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"230 ","pages":"Article 116010"},"PeriodicalIF":7.1,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145218172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}